Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acumen Pharmaceuticals, Inc. (ABOS : NSDQ)

• Company Description    Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $3.47 Daily Weekly Monthly 20 Day Moving Average: 192,578 shares Shares Outstanding: 40.50 (millions) Market Capitalization: $140.54 (millions) Beta: 52 Week High: $26.98 52 Week Low: $3.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.32% -3.50% 12 Week -35.50% -29.09% Year To Date -48.67% -37.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 427 PARK ST. - CHARLOTTESVILLE,VA 22902 USA ph: 434-297-1000 fax: - investors@acumenpharm.com http://www.acumenpharm.com

• General Corporate Information    Officers Daniel O'Connell - Chief Executive Officer William Matthew Zuga - Chief Financial Officer and ChiefBusiness Officer Nathan B. Fountain - Director Jeffrey L. Ives - Director Sean Stalfort - Director Peer Information Acumen Pharmaceuticals, Inc. (CORR.) Acumen Pharmaceuticals, Inc. (RSPI) Acumen Pharmaceuticals, Inc. (CGXP) Acumen Pharmaceuticals, Inc. (BGEN) Acumen Pharmaceuticals, Inc. (GTBP) Acumen Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00509G209 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 40.50 Most Recent Split Date: (:1) Beta: Market Capitalization: $140.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.99% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -17.45 12/31/21 - -55.59 09/30/21 - -221.88 ROA 03/31/22 - -13.08 12/31/21 - -29.40 09/30/21 - -35.55 Current Ratio 03/31/22 - 48.81 12/31/21 - 38.60 09/30/21 - 137.62 Quick Ratio 03/31/22 - - 12/31/21 - 38.60 09/30/21 - 137.62 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -28,271.13 Book Value 03/31/22 - 5.34 12/31/21 - 5.56 09/30/21 - 5.77 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©